You searched for "diabetes"
Erythropoietin in healing corneal epithelial defects in rabbits
1 December 2013
| Bheemanagouda Patil
|
Cornea / External Eye Disease
Corneal epithelial defects heal slowly in patients with diabetes, limbal stem cell deficiency and severe chemical burns. Erythropoietin is a glycoprotein hormone that promotes red blood cell proliferation and inhibits apoptosis of erythroid progenitors as well as nonhematopoietic cells. In...
Retrobulbar amphotericin B for rhino-orbital-cerebral mucormycosis
Rhino-orbital-cerebral mucormycosis (ROCM) is a rare and often fatal infection usually occurring in immunocompromised patients from diseases such as diabetes, haematological malignancy and solid organ transplantation. Current standards of care include systemic antifungal therapy and debridement, including exenteration. This study...From the seas to OCTs, a journey from working in TV to creating teaching in ophthalmology
1 April 2020
| Paul Dimmock
|
Ophthalmology
To relaunch our Allied Professionals section, Paul Dimmock from Gloucestershire discusses his unique role with the Gloucestershire Retinal Education Group. In Gloucestershire we have a collection of ophthalmic-targeted departments led by Professor Peter Scanlon, Clinical Director of the NHS Diabetic...
Control of bleeding with diabetic vitrectomy under air
1 August 2019
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Air-perfused membrane dissection, fibrovascular membrane, proliferative diabetic retinopathy, vitrectomy
The authors describe a modified diabetic vitrectomy using continuous air infusion in diabetic eyes with severe fibrovascular proliferation. In their case series of 25 eyes (20 patients), intravitreal bevacizumab (1.25mg) was used one week prior to surgery. Fifteen eyes had...
Aflibercept, bevacizumab or ranibizumab for DMO
1 August 2016
| Brian Ang
|
Retina / Uvea / Vitreous
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...
Macular oedema after cataract surgery in diabetic patients
1 December 2013
| Lorraine North
|
Retina / Uvea / Vitreous
The authors describe a multi-centre prospective observational study of 293 participants that underwent cataract surgery who all had diabetic retinopathy without definite central-involved macular oedema. Forty-five clinical sites took part throughout the United States. Patients were eligible if there was...
A paradigm shift in the way we approach cataract surgery
1 February 2015
| Nicholas Lee
|
Cataract and Refractive
Cataract surgery is the most common elective surgical procedure in the UK [1], with in the region of 350,000 cases being conducted each year. With an ageing population, this figure will only continue to rise over time. Cataract surgery is...
Diabetic Retinopathy Network laser training programme
5 February 2020
| Nick Astbury, Denise Mabey, Joachim Kilemile, William Makupa, Marcia Zondervan
|
Ophthalmology, EYE - Vitreo-Retinal
The VISION 2020 Diabetic Retinopathy Network (DR-NET) was established in 2014 to tackle the increasing burden of diabetes and diabetic retinopathy (DR) in developing countries [1]. By forming a network of long-term LINK capacity-building partnerships, learning and best practice can...
Comparing femtosecond laser assisted-DMEK to manual DMEK
1 August 2019
| Bushra Thajudeen
|
Cataract and Refractive
Femtosecond laser is as a novel tool for performing precise descemetorhexis in descemet membrane endothelial keratoplasty (DMEK) surgery. In DMEK surgery, the recipient’s Descemet membrane is peeled to allow adherence of the donor DMEK tissue to the recipient’s stroma. Complete...
Intravitreal bevacizumab vs. triamcinolone in patients with DMO at the time of cataract surgery
1 October 2016
| Anjali Gupta
|
Retina / Uvea / Vitreous
|
bevacizumab, cataract surgery, diabetic macular oedema, randomized clinical trial, triamcinolone
This prospective, single masked randomised control trial (RCT) compared visual and anatomical outcomes when either intravitreal bevacizumab (BVB) or triamcinolone (TA) was administered at the time of cataract surgery and at subsequent review, if required, in patients with diabetic macula...
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema
1 April 2015
| Jonathan CP Roos
|
Retina / Uvea / Vitreous
Macular oedema (MO) is a leading cause of visual impairment in patients with diabetic retinopathy. Whilst laser photocoagulation therapy has been the proven treatment for decades, studies over the last five years have also established a role for anti-VEGF agents...
Prognostic information for PRP-naive patients
1 February 2015
| Saruban Pasu
|
Retina / Uvea / Vitreous
The Diabetic Retinopathy Study group demonstrated that pan retinal laser photocoagulation (PRP) reduces severe vision loss by up to 50% in cases of proliferative diabetic retinopathy (PDR). The authors of this current study aimed to provide information for laser naive...